MARKET

CANF

CANF

CAN FITE BIOPHAR
AMEX

Real-time Quotes | Nasdaq Last Sale

2.440
+0.050
+2.09%
Closed 16:00 11/15 EST
OPEN
2.320
PREV CLOSE
2.390
HIGH
2.450
LOW
2.320
VOLUME
33.17K
TURNOVER
--
52 WEEK HIGH
25.95
52 WEEK LOW
1.900
MARKET CAP
8.11M
P/E (TTM)
-0.0322
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CANF and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CANF News

  • The Week In Cannabis: Stocks Fall On Poor Earnings, More Americans Support Legalization
  • Benzinga.1d ago
  • Can-Fite Obtains Patent For Treatment Of Osteoarthritis In Mammals
  • Benzinga.5d ago
  • Can-Fite Obtains Patent For Treatment Of Osteoarthritis In Mammals
  • Benzinga.5d ago
  • Can-Fite Granted US Patent for Piclidenoson in the Treatment of Osteoarthritis
  • Benzinga.5d ago

More

Industry

Biotechnology & Medical Research
+1.25%
Pharmaceuticals & Medical Research
+1.34%

Hot Stocks

Name
Price
%Change

About CANF

Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases. The Company has a research infrastructure including research laboratories and animal house facilities run by the development team. Can Fite Biofarma Ltd signed distribution contracts with a Kwang Dong Pharmaceutical Co. allowing distribution of CF101 for arthritis in Korea and Seikagaku Corp. for distribution in Japan. The Company operates three subsidiaries, Ultratrend Ltd, EyeFite Ltd and OphathaliX Inc.
More

Webull offers Can Fite Biopharma Ltd (CANF) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.